Xenon Pharmaceuticals
XENE
32 hedge funds and large institutions have $25.9M invested in Xenon Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 8 increasing their positions, 3 reducing their positions, and 5 closing their positions.
167% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 3
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
3% more funds holding
Funds holding: 31 → 32 (+1)
0.92% less ownership
Funds ownership: 51.79% → 50.87% (-0.92%)
6% less capital invested
Capital invested by funds: $27.5M → $25.9M (-$1.63M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| 1 |
SSA
Schonfeld Strategic Advisors
New York
|
+$299K |
| 2 |
Renaissance Technologies
New York
|
+$252K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$205K |
| 4 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
+$150K |
| 5 |
DMK
David M. Knott
|
+$133K |
Top Sellers
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$673K |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$544K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$274K |
| 4 |
JGC
J. Goldman & Co
New York
|
-$214K |
| 5 |
IPC
Invesco Private Capital
New York
|
-$92.2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $24K | -$274K | -100,840 | -92% |
|
|
IVM
27
InterWest Venture Management
San Francisco,
California
| $23K | – | – | – |
|
28
Macquarie Group
Sydney, NSW 2000,
Australia
| $9K | +$8.97K | +3,300 | New |
|
29
Wells Fargo
San Francisco,
California
| $7K | – | – | – |
|
30
Citigroup
New York
| $2K | – | – | – |
|
|
FDCDDQ
31
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $113 | – | – | – |
|
|
SFM
32
Sphera Funds Management
Tel Aviv,
Israel
| – | -$673K | -228,029 | Closed |
|
|
JGC
33
J. Goldman & Co
New York
| – | -$214K | -72,400 | Closed |
|
34
JP Morgan Chase
New York
| – | -$27K | -9,226 | Closed |
|
35
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$10K | -3,280 | Closed |
|
|
TRCT
36
Tower Research Capital (TRC)
New York
| – | -$1K | -325 | Closed |
|
|
CSS
37
Cubist Systematic Strategies
Stamford,
Connecticut
| – | +$272 | +100 | New |
|
XENE Hedge Fund Activity: Q4 2017 in Review
32 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q4 2017, worth a combined $25.9M — down 5.9% from $27.5M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new XENE positions and 5 closed out — a net gain of 1 holder — while 8 added to existing stakes and 3 trimmed.
The largest buyer was Schonfeld Strategic Advisors, adding an estimated $299K. The largest seller was Sphera Funds Management, exiting entirely with an estimated $673K sold.
- 32 institutional investors held Xenon Pharmaceuticals (XENE) as of Q4 2017, up from 31 in Q3 2017.
- Funds reported $25.9M of Xenon Pharmaceuticals stock for Q4 2017, down 5.9% quarter-over-quarter.
- 6 funds opened new Xenon Pharmaceuticals positions in Q4 2017 and 5 closed out, a net change of +1 holder.
- The largest Xenon Pharmaceuticals buyer in Q4 2017 was Schonfeld Strategic Advisors, an estimated $299K added.
- The largest Xenon Pharmaceuticals seller in Q4 2017 was Sphera Funds Management, an estimated $673K sold.
Based on aggregated 13F filings for Q4 2017.